From cardiac repair to cardiac regeneration--ready to translate?
Cardiovascular disease is a major public health challenge in the western world. Mortality of acute events has improved, but more patients develop HF--a condition affecting up to 22 million people worldwide. Cell transplantation is the first therapy to attempt replacement of lost cardiomyocytes and vasculature to restore lost contractile function. Since the first reported functional repair after injection of autologous skeletal myoblasts into the injured heart in 1998, a variety of cell types have been proposed for transplantation in different stages of cardiovascular disease. Fifteen years of preclinical research and the rapid move into clinical studies have left us with promising results and a better understanding of cells as a potential clinical tool. Cell-based cardiac repair has been the first step, but cardiac regeneration remains the more ambitious goal. Promising new cell types and the rapidly evolving concept of adult stem and progenitor cell fate may enable us to move towards regenerating viable and functional myocardium. Meeting a multidisciplinary consensus will be required to translate these findings into safe and applicable clinical tools.
Ott
Harald C
HC
Massachusetts General Hospital, Department of Surgery, Boston, MA, USA.
Taylor
Doris A
DA
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology; D002309:Cardiology / Q000639:trends*; D002318:Cardiovascular Diseases / Q000628:therapy*; D002454:Cell Differentiation; D049109:Cell Proliferation; D006801:Humans; D018485:Muscle Fibers, Skeletal / Q000166:cytology / Q000637:transplantation; D032383:Myocytes, Cardiac / Q000166:cytology / Q000637:transplantation; D010210:Papillary Muscles / Q000502:physiology*; D012038:Regeneration; D044968:Regenerative Medicine / Q000639:trends*; D033581:Stem Cell Transplantation; D023822:Tissue Engineering / Q000639:trends